Biogen Inc.

NASDAQ Global Select
Back to all articles
Neutral 0

Biogen pushing tau drug forward despite Alzheimer’s study failure

🧠 Biogen announced Phase 2 results for its Alzheimer's drug BIIB080 (diranersen) on May 14, 2026, calling them "unprecedented" despite missing the primary endpoint.

✅ The drug showed evidence of slowing cognitive decline across all tested doses, with the lowest dose proving particularly effective.

🧬 BIIB080 successfully reduced tau protein levels in patients, which form destructive tangles in Alzheimer's brains.

⚠️ Full detailed results were not released immediately but will be presented at the Alzheimer's Association International Conference in July 2026.

📉 Biogen shares fell approximately 5% Thursday morning after the announcement, following an initial premarket increase.

💡 The medication is a genetic medicine called an antisense oligonucleotide designed to block instructions for producing excess tau protein.

🤝 Ionis Pharmaceuticals originally developed BIIB080, and Biogen acquired worldwide rights through a licensing option in 2019.

📉 Biogen has been trying to shift focus toward programs with higher success likelihood after experiencing revenue declines over the past five years.

💉 The study administered the drug via intrathecal injections targeting the space between the brain and spinal cord tissues.

🧪 Patients were followed for 76 weeks, receiving active doses every 12 or 24 weeks depending on the specific dose group.

❓ Analysts noted confusion over the results because the lowest dose worked better than higher ones, contrary to expectations of a linear dose response.

⚖️ RBC Capital Markets analyst Brian Abrahams sees long-term potential but maintained restraint due to oddities around dose dependence and administration needs.

👀 Stifel analyst Paul Matteis highlighted the lack of understanding regarding why the dose response was non-linear as a key question for future evaluation.

📊 The conflicting data left investors and analysts debating whether the drug represents a pioneering approach or a commercial challenge.

🔄 BIIB080 is now being pushed forward to late-stage testing based on the strength of biomarker and efficacy data from the Phase 2 trial.

👉 Company officials plan to move onto experiments that could lead to an eventual approval application despite the current uncertainty.

Bullish Signals
  • Biogen is advancing its experimental Alzheimer's drug BIIB080 (diranersen) to late-stage testing based on the strength of biomarker and efficacy data observed in a Phase 2 trial.
  • Despite not meeting its primary endpoint, Biogen touted 'unprecedented and compelling' results from the study, which showed evidence that the drug could slow cognitive decline across all tested doses, particularly at the lowest dose.
  • The experimental medicine successfully reduced levels of tau protein, demonstrating a potential new mechanism to attack Alzheimer's by blocking cellular instructions that cause excessive tau production.
  • Full findings for this potentially pioneering genetic medicine are set to be presented at the upcoming Alzheimer's Association International Conference in July, providing further clarity on the asset's potential.
  • Analysts at RBC Capital Markets suggest that any new method of successfully targeting Alzheimer's could represent a 'big long-term win,' indicating significant upside potential if the mechanism proves robust.
  • Biogen's enthusiasm and plans to move forward into experiments that can tee up an approval application signal continued confidence in the asset's development trajectory despite mixed initial results.
Risk Factors
  • Biogen's stock fell approximately 5% on Thursday morning despite the company touting 'unprecedented and compelling' results from a Phase 2 study that failed to meet its primary endpoint.
  • The main goal of the Celia study, which was to find a dose response for BIIB080 (diranersen), was not achieved as researchers observed atypical efficacy where the lowest dose showed the strongest effect rather than higher doses.
  • Analysts from RBC Capital Markets and Stifel expressed caution, citing 'scant detail on the actual effect size,' 'oddities around dose dependence,' and an administration profile that likely needs improvement for commercial viability.
  • Biogen has posted revenue declines over much of the past five years while trying to focus its neuroscience research on programs with the highest likelihood of success, increasing pressure on this asset's performance.
  • The drug is administered via intrathecal injections every 12 or 24 weeks, which presents significant challenges for patient compliance compared to oral medications, potentially impacting commercial viability.
Full Analysis
Biogen (BIIB) decided to advance its experimental Alzheimer's drug, BIIB080 (also known as diranersen), into late-stage testing despite recent trial data failing to meet its primary endpoint. Following the May 14, 2026 report of the Phase 2 "Celia" study results, Biogen highlighted "unprecedented and compelling" secondary findings that showed the drug could slow cognitive decline across all tested doses, with the most pronounced effect observed at the lowest 60 milligram dose administered every 24 weeks. The company also noted a successful reduction in tau protein levels, which form destructive tangles in the brains of Alzheimer's patients, though it did not release detailed efficacy metrics at the time of the announcement, with full results scheduled for presentation at the Alzheimer's Association International Conference in July. The drug utilizes an antisense oligonucleotide mechanism inherited from Ionis Pharmaceuticals, which Biogen acquired worldwide rights to in 2019, and works by blocking cellular instructions that cause overproduction of tau protein via intrathecal injections targeting spinal fluid. Although the drug's efficacy appears contrary to the expected linear dose-response relationship—where higher doses typically yield better results—analysts from RBC Capital Markets and Stifel remain cautiously optimistic. RBC's Brian Abrahams noted that while the approach could represent a "big long-term win," he maintains restraint due to scant detail on effect size and oddities around dose dependence, leading to a slight decline in Biogen shares of about 5% after an initial premarket increase. Market analysts like Stifel's Paul Matteis acknowledge the open questions regarding the non-linear dose response but expressed that they are somewhat encouraged by the signal. The move forward represents a strategic shift for Biogen, which has experienced revenue declines over the past five years and is now focusing its neuroscience research on assets with the highest likelihood of success. This decision underscores Biogen's commitment to pursuing genetic medicine approaches to attack Alzheimer's, even when primary endpoints are not met, suggesting that the company sees potential in the drug's ability to reduce toxic tau effects inside and outside cells despite the initial trial shortcomings.